FGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesis

Tina Jaskoll, George Abichaker, Daniel Witcher, Frédéric Sala, Savério Bellusci, Mohammad K. Hajihosseini, Michael MelnickBMC 2005 · DOI

Abstract

The development of the submandibular salivary gland (SMG) is a complex process requiring precise signaling between tissue layers. This study identifies the FGF10/FGFR2b signaling pathway as an essential, non-redundant regulator of SMG epithelial branching and histodifferentiation. While the initial glandular bud can form in the absence of this pathway, subsequent growth and branching fail, leading to organ aplasia. Furthermore, the study demonstrates a dose-dependent requirement for FGF10 and highlights a critical discrepancy between in vitro rescue capabilities and in vivo functional redundancy.

Introduction: The Mechanics of Branching Morphogenesis

Organogenesis of the SMG involves branching morphogenesis—a process where a simple epithelial bud transforms into a complex network of ducts and secretory acini. While Fibroblast Growth Factors (FGFs) were known to participate in this "dialogue" between epithelium and mesenchyme, specific questions remained regarding the necessity of the FGF10/FGFR2b pathway:

  1. Agenesis vs. Aplasia: Is the pathway required for the very first initiation of the gland, or for its subsequent maintenance?
  2. Dosage Sensitivity: Does the loss of a single allele (heterozygosity) impair development?
  3. Redundancy: Can other FGFs, such as FGF8, compensate for the loss of FGF10 in a living embryo?

Methodology

The researchers utilized a combination of genetic mouse models and in vitro organ cultures.

  • Genetic Models: Analysis of $Fgf10$ and $Fgfr2b$ null (-/-) and heterozygous (+/-) mice, as well as double heterozygotes ($Fgfr2c^{+/\Delta}/Fgf10^{+/-}$), allowed for the study of gene dosage and pathway interactions in vivo.
  • Organ Culture: SMG primordia (E13-E14) were cultured to test the effects of exogenous FGF10 (gain-of-function), soluble receptor decoys (loss-of-function), and FGF8 rescue attempts.
  • Quantitative Metrics: Branching was quantified using the "Spooner ratio" (end bud number divided by initial bud number), and cell proliferation was assessed via PCNA staining.

Key Insights: Aplasia and Haploinsufficiency

A primary finding of the study is that FGF10 is required for growth and branching, but not for the initial induction of the gland. In both $Fgf10^{-/-}$ and $Fgfr2b^{-/-}$ mutants, an initial bud forms by embryonic day 12.5 (E12.5) but fails to proliferate, eventually undergoing cell death.

Histological comparison of SMG development at E12.5. (A) Wild-type (+/+) showing normal bud formation. (B) $Fgfr2b^{-/-}$ and (C) $Fgf10^{-/-}$ mutants show a rudimentary bud (SMG), indicating aplasia rather than agenesis.

The study also identified significant haploinsufficiency. Mice missing only one copy of these genes exhibited "hypoplastic" (undersized) glands. This finding is clinically relevant, as it mirrors human conditions like Aplasia of Lacrimal and Salivary Glands (ALSG), where single-copy mutations lead to significant pathology.

Results: The Power of FGF10

  • Null Phenotype: By E13.5, SMGs were completely absent in null mutants, confirming the pathway's role in maintenance.
  • Stimulation and Inhibition: In vitro, adding FGF10 increased branching by 81% and epithelial proliferation by 78%. Conversely, blocking the receptor with FGFR2b-Fc reduced branching by 22% and proliferation by 32%.
  • The In Vitro/In Vivo Paradox: While exogenous FGF8 could rescue branching in inhibited organ cultures (a 24% increase), it failed to compensate for the loss of FGF10 in vivo. This suggests that the spatial and temporal constraints within the developing embryo prevent other FGF pathways from substituting for the "master" FGF10 signal.

Discussion and Future Directions

FGF10 acts as a primary driver of epithelial cell proliferation, providing the cellular "raw material" for branching. However, it does not act in isolation. The integration of FGF10 with other signaling pathways (e.g., Shh, EGF, and TGF-$β$) to form a functional "epigenome" remains a key area for future research. Understanding why the embryo's internal environment restricts the redundant potential of factors like FGF8 will be crucial for developing regenerative therapies for salivary gland dysfunction.

Summary updated

Abstract

Our data indicates that FGF10/FGFR2b signaling is essential for the SMG epithelial branching and histodifferentiation, but not earliest initial bud formation. The functional presence of other endogenous signaling pathways could not prevent complete death of embryonic SMG cells in Fgf10 and Fgfr2b null mice. Though we were able to rescue the abnormal phenotype associated with reduced in vitro FGF10/FGFR2b signaling with exogenous FGF8 supplementation, our results indicate that the FGF10/FGFR2b and FGF8/FGFR2c are nonredundant signaling pathways essential for in vivo embryonic SMG development. What remains to be determined is the in vivo functional relationship between the FGF10/FGFR2b signal transduction pathway and other key signaling pathways, and how these pathways are integrated during embryonic SMG development to compose the functional epigenome.
BibTeX
@inproceedings{jaskoll2005fgf,
  author = {Tina Jaskoll and George Abichaker and Daniel Witcher and Frédéric Sala and Savério Bellusci and Mohammad K. Hajihosseini and Michael Melnick},
  title = {{FGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesis}},
  booktitle = {BMC},
  year = {2005},
  doi = {10.1186/1471-213x-5-11},
}
Figure